Electronically monitored adherence to medications by newly diagnosed patients with juvenile rheumatoid arthritis

Michael A Rapoff1, John M Belmont, Carol B Lindsley

  • 1University of Kansas Medical Center, Kansas City, KS 66160-7330, USA. mrapoff@kumc.edu

Arthritis and Rheumatism
|December 13, 2005
PubMed

Insights

Children with juvenile rheumatoid arthritis (JRA) adhere better to nonsteroidal anti-inflammatory drugs (NSAIDs) when they have more active joints or higher socioeconomic status. Lower socioeconomic status families need targeted adherence support.

Area of Science:

  • Pediatric Rheumatology
  • Pharmacology
  • Health Services Research

Background:

  • Juvenile rheumatoid arthritis (JRA) is a chronic condition requiring long-term medication adherence.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly prescribed for JRA symptom management.
  • Understanding adherence patterns is crucial for optimizing treatment outcomes in pediatric populations.

Purpose of the Study:

  • To characterize adherence rates to NSAIDs in newly diagnosed JRA patients.
  • To identify demographic and disease-related factors predicting NSAID adherence.
  • To inform targeted interventions for improving medication adherence in JRA.

Main Methods:

  • Prospective monitoring of NSAID adherence in 48 children with JRA over 28 days using electronic devices.
  • Assessment of disease activity including active joint counts and morning stiffness.
  • Collection of demographic data: age, sex, ethnicity, and socioeconomic status.

Main Results:

  • 52% of patients met an 80% adherence threshold; 48% were nonadherent.
  • Significant predictors of adherence included higher active joint counts and higher socioeconomic status.
  • A logistic regression model achieved 70.5% correct classification of adherent/nonadherent patients.

Conclusions:

  • Adherence to NSAIDs in JRA appears to be symptom-driven, with more active joints correlating with better adherence.
  • Higher socioeconomic status is associated with improved adherence, highlighting potential disparities.
  • Families with lower socioeconomic status may require additional support to ensure medication adherence.
Abstract

Related Concept Videos

Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
218
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
142
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
218
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
236
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
379
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
361